GW Pharmaceuticals PLC- ADR operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GW Pharmaceuticals PLC- ADR with three other
companies in this sector in the United States:
sales of $17.68 million
of which 67%
of which 80%
was Bronchitol and Aridol), and
Bioanalytical Systems, Inc.
Sales fell dramatically in 2016:
GW Pharmaceuticals PLC- ADR reported sales of $14.57 million
September of 2016.
decrease of 66.9%
versus 2015, when the company's sales were $43.99 million.
Contributing to the drop in overall sales was the 85.6% decline
in Sativex R&d, from $34.34 million to $4.94 million.
There were also decreases in sales in
Pipeline R&d (down 42.3% to $476,036.09 )
However, these declines were partially offset by the increase in sales of
Commercial (up 3.6% to $9.15 million)